PRESS RELEASE – PRIVILEGED INFORMATION The developed Medsenic’s composition-of-matter patent family does cover the therapeutic use of arsenic salts and metal ions through various routes of...
PRESS RELEASE – PRIVILEGED INFORMATION The adapted supply and commercialization conditions to better achieve the development of the first oral formulation of arsenic trioxide for the treatment of...
Biotechnology company BioSenic’s affiliate Medsenic has amended its licence agreement with Australia-based pharmaceutical company Phebra for the oral formulation of arsenic trioxide (OATO).
BioSenic announces the approval and publication of the Prospectus for listing and admission to trading of the shares and subscription rights issued in the context of the capital increase by way of in kind contributions of Medsenic
A complex fracturing at Bone brings orthopedic biotechs in reverse merger deal
Mont-Saint-Guibert, Belgium, August 10, 2022, 12:00 AM CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the cell therapy company addressing unmet medical needs in orthopedics and Medsenic, a privately held, clinical stage biopharmaceutical company incorporated in France and specialized in the development of optimized formulations of arsenic salts and their application in inflammatory conditions and other potential new indications, today announces the signature of a binding contribution agreement to combine the operations of both companies by means of a share for share exchange, subject to the approval of the shareholders' meeting.
STRASBOURG, France--(BUSINESS WIRE)--Medsenic, a clinical stage biopharmaceutical company focusing on the discovery and development of new indications and formulations of arsenic salts for the treatment of severe autoimmune diseases, announced today a new publication in Transplantation and Cellular Therapy, - the official Journal of ASTCT (American Society for Transplantation and Cellular Therapy) - that provides insights from its drug Arscimed®, a GMP intravenous formulation of arsenic trioxide, in patients with Chronic Graft Versus Host Disease (cGvHD).
STRASBOURG, France--(BUSINESS WIRE)--Medsenic, a clinical-stage biopharmaceutical company focusing on the discovery and development of new indications and formulations of arsenic salts for the treatment of severe autoimmune diseases, announced today the positive conclusions of the pre-IND (Investigational New Drug) meeting with the US Food and Drug Administration (FDA).
STRASBOURG, France--(BUSINESS WIRE)--Medsenic, a clinical-stage biopharmaceutical company specializing in the discovery and development of new indications and formulations of arsenic salts for the treatment of severe autoimmune diseases, today announced that it has received from the US Patent and Trademark Office (USPTO) with Arscimed®, a notice allowance for a patent which enhances in the United States the protection of its intravenous formulation of arsenic trioxide, particularly in SLE repair.